Scienture (NASDAQ:SCNX) Now Covered by Maxim Group

Equities researchers at Maxim Group started coverage on shares of Scienture (NASDAQ:SCNX) in a research report issued on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $1.50 price target on the stock. Maxim Group’s price target indicates a potential upside of 298.94% from the stock’s current price.

A number of other brokerages have also commented on SCNX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Scienture in a research note on Monday, December 29th. Wall Street Zen lowered shares of Scienture from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Scienture presently has an average rating of “Hold” and a consensus target price of $1.50.

Scienture Price Performance

Scienture stock traded up $0.00 during trading hours on Tuesday, reaching $0.38. The company had a trading volume of 111,870 shares, compared to its average volume of 1,025,667. The company has a 50-day moving average price of $0.49 and a 200 day moving average price of $0.74. The firm has a market cap of $15.28 million, a price-to-earnings ratio of -0.38 and a beta of 3.02. Scienture has a 12-month low of $0.37 and a 12-month high of $3.61.

Institutional Investors Weigh In On Scienture

An institutional investor recently bought a new position in Scienture stock. Virtu Financial LLC bought a new position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned approximately 0.22% of Scienture as of its most recent filing with the Securities and Exchange Commission (SEC). 5.68% of the stock is owned by institutional investors and hedge funds.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.